Combes Laura, Sawkulycz Xenia, Fang Wen-Hui, Guo Baoqiang, Slevin Mark
Department of Life Sciences, Manchester Metropolitan University, Manchester, UK.
Department of Biological and Geographical Sciences University of Huddersfield, Huddersfield, UK.
Biophys Rep. 2021 Apr 30;7(2):81-90. doi: 10.52601/bpr.2021.200025.
Stem cell therapy is a promising treatment for neurogenerative disease as well as inflammatory and immune mediated diseases. Decades of preclinical research has demonstrated stem cell ability to differentiate into multiple cell lineages and be utilised in regeneration and repair with their immunomodulatory and immunosuppressive properties. This work has provided the fundamental scientific knowledge needed to launch various clinical trials studying stem cell therapy in autoimmune disorders, stroke, and other tissue injury. Despite the early success many of these promising therapies are yet to breakthrough into clinical use. In this review, we highlight the recent developments in the use of stem cells as therapeutic agents for neurological conditions as well as their failures and how the clinical translation can be improved.
干细胞疗法是治疗神经退行性疾病以及炎症和免疫介导疾病的一种很有前景的治疗方法。数十年的临床前研究已证明干细胞能够分化为多种细胞谱系,并凭借其免疫调节和免疫抑制特性用于再生和修复。这项工作提供了开展各种临床试验所需的基础科学知识,这些试验研究干细胞疗法在自身免疫性疾病、中风和其他组织损伤中的应用。尽管这些很有前景的疗法中有许多早期取得了成功,但尚未突破到临床应用阶段。在这篇综述中,我们重点介绍了将干细胞用作神经疾病治疗药物的最新进展、它们的失败之处以及如何改进临床转化。